These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 19318364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, de Requena DG, Prestini K, Parisi SG, Bonora S, Palù G, Carosi G.
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [Abstract] [Full Text] [Related]

  • 3. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 4. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
    Perrella A, Sbreglia C, D'Antonio A, Atripaldi L, Perrella O.
    Clin Microbiol Infect; 2010 Jun; 16(6):676-8. PubMed ID: 19681945
    [Abstract] [Full Text] [Related]

  • 5. Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
    Honda H, Gatanaga H, Matsumura J, Kamimura M, Goto K, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S.
    Int J STD AIDS; 2009 Jun; 20(6):441. PubMed ID: 19451340
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 8. Anti-HIV agents. Saquinavir with fosamprenavir.
    TreatmentUpdate; 2004 Aug; 16(3):9. PubMed ID: 17219609
    [No Abstract] [Full Text] [Related]

  • 9. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
    Saumoy M, Tiraboschi J, Gutierrez M, Niubó J, Domingo P, Vila A, Podzamczer D.
    HIV Med; 2011 Aug; 12(7):438-41. PubMed ID: 21729229
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Heart attack warning issued.
    AIDS Patient Care STDS; 2010 Jan; 24(1):65-6. PubMed ID: 20169638
    [No Abstract] [Full Text] [Related]

  • 12. Safety of fosamprenavir in a cohort of HIV-1-infected patients with co-morbidities.
    Esposito V, Chiodini P, Viglietti R, Parrella R, Parrella G, Maddaloni A, Sangiovanni V, Gargiulo M, Abrescia N, Chirianni A.
    In Vivo; 2011 Jan; 25(5):813-9. PubMed ID: 21753139
    [Abstract] [Full Text] [Related]

  • 13. Fosamprenavir: drug development for adherence.
    Hester EK, Chandler HV, Sims KM.
    Ann Pharmacother; 2006 Jan; 40(7-8):1301-10. PubMed ID: 16757678
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, Bonora S, Motta A, Luzi K, Pecorari M, Gennari W, Masetti M, Gerunda GE, Esposito R.
    Transplant Proc; 2006 May; 38(4):1138-40. PubMed ID: 16757288
    [Abstract] [Full Text] [Related]

  • 15. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract] [Full Text] [Related]

  • 16. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F, Fosamprenavir Expanded Access Program Group.
    Enferm Infecc Microbiol Clin; 2009 Jan 28; 27(1):28-32. PubMed ID: 19218000
    [Abstract] [Full Text] [Related]

  • 17. Fosamprenavir: a new PI option. Interview by Craig Sterritt.
    Nadler J.
    IAPAC Mon; 2004 Feb 28; 10(2):50-2. PubMed ID: 15106520
    [No Abstract] [Full Text] [Related]

  • 18. Four posters add to our knowledge of Lexiva.
    Proj Inf Perspect; 2008 Dec 28; (47):7-8. PubMed ID: 19227558
    [No Abstract] [Full Text] [Related]

  • 19. FDA notifications. FDA approves NDA for Lexiva.
    AIDS Alert; 2007 Dec 28; 22(12):142. PubMed ID: 18415960
    [No Abstract] [Full Text] [Related]

  • 20. Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C.
    Macías J, Mira JA, Vergara S, Pineda JA.
    Hepatology; 2005 Aug 28; 42(2):498; author reply 498-9. PubMed ID: 15880585
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.